Innovent Biologics Inc(1801)

Description: Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, and manufacture of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin's lymphoma, and esophageal carcinoma. The company also offers Byvasda for the treatment of several malignant tumors; Halpryza for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and Wegener's granulomatosis; Pemazyre for the treatment of adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib for the treatment of adult patients with tyrosine kinase inhibitor; and Cyramza to treat four different types of cancers. In addition, it engages in the development of IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein for ocular fundus disease; IBI-306, a human monoclonal antibody to treat hypercholesterolemia; IBI-310, a recombinant human anti CTLA-4 monoclonal antibody for liver cancer and renal cell carcinoma. Further the company develops IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for the treatment of adults with relapsed or refractory multiple myeloma; IBI-376 for the treatment of recurrent or refractory follicular lymphoma; and IBI-112 for the treatment of psoriasis. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. The company has strategic collaborations with NeoCura Bio-Medical Technology Co. Ltd.; Roche Group; Ascentage Pharma Group International; Eli Lilly and Company; Roche Group; and Bolt Biotherapeutics, Inc. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.

---

Keywords: Medicine Biotechnology Cancer Biopharmaceutical Clinical Medicine Pharmaceutical Products Immunology Immune System Treatment Of Cancer Cancer Treatment Cell Therapy Lymphoma Monoclonal Antibody Psoriasis Metabolic Disease Liver Cancer Chimeric Antigen Receptor T Cell Renal Cell Carcinoma Hypercholesterolemia Chronic Lymphocytic Leukemia Hodgkin Treatment Of Psoriasis CD47 Refractory Multiple Myeloma Cyramza Treatment Of Non Hodgkin's Lymphoma Esophageal Carcinoma Hodgkin's Lymphoma Ibi 302 Metastatic Cholangiocarcinoma Wegener Wegener's Granulomatosis

---

Home Page: www.innoventbio.com

168 Dongping Street
Suzhou, 215123
China
Phone: 86 512 6956 6088

---

Officers

Exchange: HK

Country: HK : Hong Kong

Currency: Hong Kong Dollar (HK$)